- American City Business Journals•11 hours ago
The head of the pharmaceutical industry’s biggest Washington lobby group visited Boston on Tuesday as part of a public relations campaign aimed at countering criticism of high drug prices — and singled out Cambridge-based Biogen for praise. During a question-and-answer session with reporters Tuesday, Stephen Ubl, the head of the Pharmaceutical Research and Manufacturers of America, spoke out against what he called a handful of “bad actors” — companies that purchase off-patent medicines that lack generic competition and then significantly raise the price. As an example, he pointed to Biogen’s (BIIB) Spinraza, which in December became the first drug approved to treat spinal muscular atrophy, a leading genetic cause of death in infants.
- Investopedia•2 days ago
Celgene’s multiple sclerosis drug ozanimod beat rival Avonex in a Phase 3 study.
- Motley Fool•2 days ago
Healthcare bargains abound for patient long-term investors.
BIIB : Summary for Biogen Inc. - Yahoo Finance
Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
|Bid||287.10 x 900|
|Ask||287.98 x 100|
|Day's Range||286.22 - 289.91|
|52 Week Range||223.02 - 333.65|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||16.95|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|